Restoring Immune Mediated Disease Control by Ipilimumab Re-exposition in a Heavily pretreated Patient With MSI-H mCRC

Clin Colorectal Cancer. 2022 Sep;21(3):e148-e151. doi: 10.1016/j.clcc.2022.01.003. Epub 2022 Jan 8.

Abstract

Background: Immune-Checkpoint-inhibitors (ICIs) are approved in first line therapy of microsatellite-instable, deficient miss-match-repair (MSI-H-dMMR) metastatic colorectal cancer (mCRC), and in second line after standard chemotherapy. Evidence supporting immunotherapy after immunotherapy is scarce.

Case report: This case report highlights the course of a heavily pretreated patient with MSI-H mCRC with progression after multiple local therapies, standard chemotherapies and pembrolizumab. After 4 cycles of ipilimumab and nivolumab followed by nivolumab-maintenance he achieved a long-lasting disease control of 22 months. After further subsequent progression he regained immune mediated disease control by a second "boost" of ipilimumab.

Conclusion: Re-exposition with ipilimumab is a potential option to restore immune-mediated-disease-control in patients with preceding long-lasting response to ipilimumab/nivolumab and with dMMR-tumors. The clinical situation of progress after long-lasting disease control on ICIs becomes more common and is an opportunity to investigate potential strategies for restoring immune mediated disease control.

Keywords: Ipilimumab after ipilimumab; Ipilimumab-boost; MSI-H metastatic colorectal cancer; Re-exposition ipilimumab; Reinduction ipilimumab.

Publication types

  • Case Reports

MeSH terms

  • Colonic Neoplasms* / drug therapy
  • Colorectal Neoplasms* / drug therapy
  • Colorectal Neoplasms* / genetics
  • Colorectal Neoplasms* / pathology
  • DNA Mismatch Repair
  • Humans
  • Immunotherapy
  • Ipilimumab / pharmacology
  • Ipilimumab / therapeutic use
  • Male
  • Microsatellite Instability
  • Nivolumab / therapeutic use

Substances

  • Ipilimumab
  • Nivolumab